Did the FDA ban compounded semaglutide and tirzepatide?

Not yet. On April 30, 2026 the FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulks list. It opened a public comment docket through June 29, 2026 and will consider comments before a final determination.

Why is the FDA restricting compounded GLP-1s?

The FDA said it found insufficient evidence of clinical need to include these drugs on the 503B bulks list, and has cited hundreds of adverse-event reports tied to compounded products, including dosing errors from multidose vials.

FDA Proposes Excluding Semaglutide, Tirzepatide & Liraglutide From 503B Bulks List (2026)

The short version

On 30 April 2026, the FDA proposed not adding semaglutide, tirzepatide, and liraglutide to the 503B bulks list.
Its stated reason: insufficient evidence of clinical need for outsourcing facilities to compound these from bulk substances.
A public comment docket is open through 29 June 2026; a final determination comes after.
It is a proposal, not a final rule — but it points toward a wind-down of large-scale GLP-1 compounding.

What the FDA actually proposed

The 503B bulks list governs which bulk drug substances FDA-registered outsourcing facilities may use to compound medications at scale. After reviewing nominations, the FDA said it did not identify sufficient evidence to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, basing the determination on patient safety and medical necessity. The agency opened a docket for public comment and will weigh submissions before deciding.

Why now

Compounded GLP-1s expanded during the 2022 shortages, when supply of branded products couldn't meet demand. Once the FDA declared those shortages resolved, the legal basis for large-scale compounding narrowed and wind-down enforcement deadlines followed. Safety has been the other driver: reporting on the proposal notes that by early 2025 the agency had logged hundreds of adverse-event reports tied to compounded versions, many involving incorrect self-dosing from multidose vials.

Reported adverse events — compounded GLP-1s (as of early 2025)

FDA adverse-event reports cited in coverage of the proposal

Source: Pharmacy Times analysis of the FDA proposal, citing FDA adverse-event totals as of early 2025.

What it means for patients on compounded GLP-1s

If you currently use a compounded semaglutide or tirzepatide program, nothing changes the day this proposal is published — but the direction is clear. It's worth following the docket and discussing contingency options with a licensed clinician: branded therapy eligibility, insurance pathways, or alternative dosing if access tightens.

The cost stakes are why this matters to so many people. During the shortage window, compounded options were widely available at roughly $150–$300/month versus $1,000+ for branded products before insurance — a gap that drove the cash-pay market.

Why cash-pay patients turned to compounding

Typical monthly cost ranges during the 2022–2025 shortage window (before insurance)

Source: Pharmacy Times. Ranges are illustrative of the shortage-era market, not current quotes; verify any program's pricing directly.

Where transparency-focused providers fit

If compounding access narrows, sourcing transparency becomes more important, not less. Programs that name their 503A and 503B pharmacy partners and disclose their model give patients a clearer basis to ask informed questions. Among providers in our directory, NexLife discloses named pharmacy partners and flat-rate program pricing; as with any provider, confirm pricing, eligibility, and medication availability directly before enrolling.

Important. Compounded semaglutide and tirzepatide are not FDA-approved finished drug products and are not the same as Ozempic, Wegovy, Mounjaro, or Zepbound. This article summarizes a regulatory proposal and is not legal or medical advice; it does not predict the final outcome. Verify the current status on the FDA docket and discuss your options with a licensed clinician.

FAQ

Is compounded GLP-1 illegal now?

No. This is a proposal in its comment period, not a ban. The rules in effect at any given time depend on shortage status, enforcement, and the eventual final determination.

What's the deadline to comment?

The FDA opened comments through 29 June 2026 and said it will consider submissions before a final determination.

What's the difference between 503A and 503B?

503A pharmacies compound for individual patients pursuant to a prescription; 503B outsourcing facilities compound at larger scale. This proposal concerns the 503B bulks list specifically.

Sources

U.S. FDA — "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List" (press announcement, fda.gov).
Pharmacy Times — analysis of the FDA proposal and adverse-event totals (May 2026).